Haojun Ouyang

897 total citations
15 papers, 137 citations indexed

About

Haojun Ouyang is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Haojun Ouyang has authored 15 papers receiving a total of 137 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 6 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Haojun Ouyang's work include Neurogenetic and Muscular Disorders Research (9 papers), CRISPR and Genetic Engineering (2 papers) and RNA modifications and cancer (2 papers). Haojun Ouyang is often cited by papers focused on Neurogenetic and Muscular Disorders Research (9 papers), CRISPR and Genetic Engineering (2 papers) and RNA modifications and cancer (2 papers). Haojun Ouyang collaborates with scholars based in United States, United Kingdom and Hungary. Haojun Ouyang's co-authors include Symantha Melemed, D. Ferry, Kei Muro, Rebecca R. Hozak, Eric Van Cutsem, G. Bodoky, Robert J. Konrad, Allen Lee Cohn, Tudor–Eliade Ciuleanu and Josep Tabernero and has published in prestigious journals such as Neurology, Annals of Oncology and Journal of the Neurological Sciences.

In The Last Decade

Haojun Ouyang

15 papers receiving 137 citations

Peers

Countries citing papers authored by Haojun Ouyang

Since Specialization

Citations

This map shows the geographic impact of Haojun Ouyang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haojun Ouyang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haojun Ouyang more than expected).

Fields of papers citing papers by Haojun Ouyang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haojun Ouyang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haojun Ouyang. The network helps show where Haojun Ouyang may publish in the future.

Co-authorship network of co-authors of Haojun Ouyang

This figure shows the co-authorship network connecting the top 25 collaborators of Haojun Ouyang. A scholar is included among the top collaborators of Haojun Ouyang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haojun Ouyang. Haojun Ouyang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	S12 Onasemnogene abeparvovec gene therapy for spinal muscular atrophy type 1: phase 3 study (STR1VE-US) 2021 ·John Day, (unknown), (unknown), Basil T. Darras, ST Iannaccone, (unknown), (unknown), (unknown), (unknown), T. B. B. Crawford, (unknown), (unknown), (unknown), Megan L. Schultz, (unknown), Deepa H. Chand, Sitra Tauscher‐Wisniewski, Haojun Ouyang, (unknown), (unknown)	2
2	SMA – THERAPY 2020 ·Neuromuscular Disorders ·Omar Dabbous, (unknown), (unknown), Francis G. Ogrinc, (unknown), Haojun Ouyang, (unknown), (unknown), (unknown), (unknown)	1
3	SMA – THERAPY 2020 ·Neuromuscular Disorders ·Jerry R. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, (unknown), (unknown), N. Miller, M. Iammarino, (unknown), Francis G. Ogrinc, Haojun Ouyang, (unknown), (unknown), Douglas M. Sproule, Matthew N. Meriggioli, Douglas E. Feltner, (unknown)	2
4	Gene-Replacement Therapy in Spinal Muscular Atrophy Type 1: Long-Term Follow-Up From the Onasemnogene Abeparvovec-xioi Phase 1/2a Clinical Trial (1808) 2020 ·Neurology ·Jerry R. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, Linda Lowes, Lindsay N. Alfano, N. Miller, M. Iammarino, Kathleen Church, Francis G. Ogrinc, Haojun Ouyang, (unknown), (unknown), Douglas M. Sproule, Matthew N. Meriggioli, Douglas E. Feltner, Samiah Al-Zaidy	3
5	Establishing Clinical Trial Readiness of the Rett Syndrome Hand Function Measure (P1.6-034) 2019 ·Neurology ·Helen Leonard, Tim A. Benke, Pamela S. Diener, Douglas E. Feltner, Petra Kaufmann, David N. Lieberman, (unknown), Thomas A. Macek, Bryan E. McGill, (unknown), (unknown), Jeffrey L. Neul, Joan A. O’Keefe, Haojun Ouyang, Alan K. Percy, Daniel Tarquinio, Jenny Downs	2
6	P.351Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial 2019 ·Neuromuscular Disorders ·J. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, (unknown), Lindsay N. Alfano, N. Miller, M. Iammarino, (unknown), Francis G. Ogrinc, Haojun Ouyang, (unknown), Sunil Shah, James L’Italien, (unknown), (unknown), (unknown)	1
7	P.349Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy Type 1 (SMA1): Pivotal phase 3 study (STR1VE) update 2019 ·Neuromuscular Disorders ·John Day, Claudia A. Chiriboga, Thomas O. Crawford, Basil T. Darras, (unknown), Anne M. Connolly, Susan T. Iannaccone, (unknown), Loren D.M. Peña, M. Schultz, Perry B. Shieh, Edward C. Smith, Douglas E. Feltner, Francis G. Ogrinc, Haojun Ouyang, Thomas A. Macek, (unknown), (unknown), (unknown), J. Mendell	2
8	Study Design of STR1VE-EU, a Phase 3 Trial of AVXS-101 Gene-Replacement Therapy (GRT) in Patients With Spinal Muscular Atrophy Type 1 (SMA1) in Europe 2019 ·Neuropediatrics ·Francesco Muntoni, Giovanni Baranello, Claudio Bruno, Stefania Corti, Riccardo Masson, Volker Straub, Giuseppe Vita, (unknown), (unknown), Susan Williamson, Haojun Ouyang, Douglas E. Feltner, Matthew N. Meriggioli, Arseniy Lavrov, James L’Italien, Douglas M. Sproule, Eugenio Mercuri	2
9	Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial 2019 ·Journal of the Neurological Sciences ·Jerry R. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, Linda Lowes, Lindsay N. Alfano, N. Miller, M. Iammarino, (unknown), Sidney A. Spector, Francis G. Ogrinc, Haojun Ouyang, (unknown), (unknown), James L’Italien, (unknown), Douglas E. Feltner, (unknown)	4
10	Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Onasemnogene Abeparvovec Phase 1/2 Clinical Trial 2019 ·Neuropediatrics ·Jerry R. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, Linda Lowes, Lindsay N. Alfano, N. Miller, M. Iammarino, Kathleen Church, (unknown), Francis G. Ogrinc, Haojun Ouyang, (unknown), (unknown), James L’Italien, Douglas M. Sproule, Douglas E. Feltner, Samiah Al-Zaidy	2
11	Contributors to the substantial variation in on‐treatment testosterone levels in men receiving transdermal testosterone gels in randomized trials 2017 ·Andrology ·Shalender Bhasin, Thomas G. Travison, Lisa M. O’Brien, (unknown), Venkatesh Krishnan, Haojun Ouyang, Karol M. Pencina, Shehzad Basaria	12
12	Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study 2017 ·Annals of Oncology ·Josep Tabernero, Rebecca R. Hozak, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Jana Prausová, Kei Muro, Robert W. Siegel, Robert J. Konrad, Haojun Ouyang, Symantha Melemed, D. Ferry, Federico Nasroulah, Eric Van Cutsem	78
13	O-007 Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study 2016 ·Annals of Oncology ·Eric Van Cutsem, Kei Muro, David Cunningham, G. Bodoky, Alberto Sobrero, Stefano Cascinu, Jaffer A. Ajani, Atsushi Ohtsu, (unknown), S-E. Al-Batran, Zev A. Wainberg, Rebecca R. Hozak, Haojun Ouyang, Symantha Melemed, D. Ferry, H. Wilke	5
14	Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors 2015 ·Investigational New Drugs ·Sandrine Faivre, Anthony J. Olszanski, K. Weigang-Köhler, Hanno Riess, Roger B. Cohen, Xuejing Wang, Scott P. Myrand, Enaksha Wickremsinhe, Candice L. Horn, Haojun Ouyang, Sophie Callies, Karim A. Benhadji, Éric Raymond	11
15	A Phase 2, Placebo-Controlled Study of the Opioid Receptor Antagonist LY2196044 for the Treatment of Alcohol Dependence 2013 ·Alcoholism Clinical and Experimental Research ·Conrad J. Wong, Jennifer Witcher, Craig Mallinckrodt, Robert A. Dean, Raymond F. Anton, Yun-Fei Chen, Bonnie A. Fijal, Haojun Ouyang, (unknown), Scott S. Sundseth, Kory Schuh, Bruce J. Kinon	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact